Latest News
Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy of immune-checkpoint inhibitors (ICIs). Herein, the authors review studies that have evaluated the roles of various TIL subsets as predictive biomarkers for ICIs, as well as opportunities, challenges and strategies for future research in this field.
- November 13, 2024
Chen Liu, MD, PhD, Chair of Yale Pathology, welcomes public school students to the 2nd Annual Yale Pathology Day, where they explored careers in pathology.
- May 06, 2024
More than half of human cancers, called “non-inflamed” or “cold” tumors, are not being effectively infiltrated by the cancer-fighting T cells. Essentially, the soldiers are excluded from the battlefield. Yale Cancer Center researchers want to know why.
- November 28, 2023
The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples.
- January 18, 2023
In this podcast, we’ll be covering the latest updates on immune checkpoint inhibitor resistance for patients with non-small cell lung cancer (NSCLC). We’ll be hearing from Professor Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, Dr Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, and Dr Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, about new developments in our understanding of mechanisms of resistance, as well as possible therapeutic options for overcoming resistance.
- January 10, 2023
Yale Cancer Center's Class of 1961 Cancer Research Awards were presented to Nikhil Joshi, PhD, and Kurt Schalper, MD, PhD, at the annual Yale Cancer Center Conclave on January 5, 2023.
- December 01, 2022Source: Bioanalysis Zone
As the world continues to grapple with the COVID-19 pandemic, we gathered experts from different disciplines to discuss the emergence of novel variants of concern and the development of cell and gene therapies, both in the past and throughout the COVID-19 pandemic.
- November 28, 2022Source: VuMedi
TAP2 Deficiency Mediates Adaptive Immune Evasion and Immunotherapy Resistance in Human NSCLC
- November 10, 2022
Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose non–small cell lung cancer has resisted immunotherapy.
- October 27, 2022Source: VJOncology
Downregulation of TAP2 and to a lesser extent, TAP1, have been found to increase immune evasion in tumors. Kishu Ranjan, PhD, Yale School of Medicine, New Haven, CT, discusses the clinical implications and future research potential for these findings. Elucidating additional mutations in TAP1/2, novel molecular targets such as RBBP7 and epigenetic modulators are crucial to exploit TAP1/2 downregulation to increase PD-L1 inhibitor efficacy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.